<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014634</url>
  </required_header>
  <id_info>
    <org_study_id>NL6719705818</org_study_id>
    <nct_id>NCT04014634</nct_id>
  </id_info>
  <brief_title>GON-injection for a Sooner and Better Treatment of Cluster Headache</brief_title>
  <acronym>CHIANTI</acronym>
  <official_title>GON-injection for a Sooner and Better Treatment of Cluster Headache: a Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hersenstichting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovatiefonds Zorgverzekeraars</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cluster headache is a very severe primary headache disorder. In episodic cluster headache,
      attacks occur in 'bouts' (clusters) lasting weeks to months. Management of cluster headache
      entails a combination of attack and prophylactic treatment. Current first choice prophylactic
      treatment (verapamil) has considerable side effects which can be serious and include possibly
      fatal cardiac arrhythmias; and it can take weeks to titrate to an effective dose. Evidence
      has emerged that local steroid injection of the greater occipital nerve (GON) may be
      effective in cluster headache, but this method has not been investigated as a first line
      prophylactic treatment in a large, well-documented group of episodic cluster headache
      patients who are still free of prophylactic medication and just entered a new cluster
      headache episode. As such, GON-injection has not yet found its way into current treatment
      protocols. The investigators plan to perform this multicentre double-blind randomized
      controlled trial to investigate whether GON-injection is efficacious as a first-line
      prophylactic treatment, aiming to remove the need for high doses of daily medication - such
      as verapamil - with associated side effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verapamil mean total dose</measure>
    <time_frame>12 week period</time_frame>
    <description>Difference in mean total dose of verapamil used during the study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days to remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>Median number of days to remission (7 consecutive days without attack)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily attacks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean number of attacks per day during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak dose verapamil</measure>
    <time_frame>12 weeks</time_frame>
    <description>Peak dose verapamil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preamature termination</measure>
    <time_frame>12 weeks</time_frame>
    <description>Premature termination of study due to need for escape medication</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Use of attack medication</measure>
    <time_frame>12 weeks</time_frame>
    <description>The total use of attack medication (stratified for oxygen and sumatriptan)</description>
  </other_outcome>
  <other_outcome>
    <measure>Daily attack severity and duration</measure>
    <time_frame>For the total study period and each of the three consecutive 4-week time periods</time_frame>
    <description>Mean number, severity (1-10) and duration of attack per day.</description>
  </other_outcome>
  <other_outcome>
    <measure>Attack-freedom</measure>
    <time_frame>days 7, 14 and 28</time_frame>
    <description>Percentage of patients that are attack-free at days 7, 14 and 28</description>
  </other_outcome>
  <other_outcome>
    <measure>Non-cluster headache</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurrence of 'non-cluster' headache (number of days and mean intensity per affected day)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of subjects with adverse-events (stratified for type of side effect (AE, SAE, SUSAR))</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective feeling</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>Subjective feeling at days 7, 14 and 28 (visual analogue scale, VAS. Scale from 0 to 10 where 0 is worst imaginable and 10 best imaginable)</description>
  </other_outcome>
  <other_outcome>
    <measure>Satisfaction score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Satisfaction score (7 point scale, 0 to 6. 0 is completely unsatisfied and 6 completely satisfied)</description>
  </other_outcome>
  <other_outcome>
    <measure>Recommendation</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>Would the patient recommend this treatment to others</description>
  </other_outcome>
  <other_outcome>
    <measure>Blinding participants</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>What treatment does the patient think he/she received (placebo/GON/uncertain)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blinding investigators</measure>
    <time_frame>Days 7, 14 and 28</time_frame>
    <description>What treatment do the investigators think the patient has had</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cluster Headache, Episodic</condition>
  <condition>Greater Occipital Nerve Injection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of NaCl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Single GON injection with methylprednisolone</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single GON-injection with NaCl</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have to be diagnosed with episodic cluster headache according to the
             international classification of headache disorders - third edition, ICHD-3

          -  Patients have to be aged 18-65 years

          -  Patients need to be newly diagnosed and treatment na√Øve, or already diagnosed and
             currently free from prophylactic treatment

          -  Patients need to have a mean of 1 or more attacks per day in the 3 days preceding
             inclusion.

          -  Patients should be in their cluster period for shorter than 4 weeks before inclusion.

        Exclusion Criteria:

          -  A contraindication for treatment with steroids or verapamil

          -  The use of anticoagulants or known bleeding disorder.

          -  Use of any prophylactic medication for cluster headache

          -  Patients with a history of other primary headache who are currently using prophylactic
             medication for this headache

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf Fronczek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roemer Brandt, MD</last_name>
    <phone>0031620063703</phone>
    <email>r.b.brandt@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rolf Fronczek, MD, PhD</last_name>
    <email>r.fronczek@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boerhaave Clinics</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emile Couturier, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roemer Brandt, MD</last_name>
      <phone>0031620063703</phone>
      <email>r.b.brandt@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <state>Zuid Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joost Haan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooi Ziekenhuis</name>
      <address>
        <city>Blaricum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Carpay, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Gerlach, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wim Mulleners, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>RolfFronczek</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All Data will be stored using Castor EDC. All hard copies will be stored in the individual centers. If requested, after study completion, data can be shared with de PIs in participating centers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

